Kymera Therapeutics (KYMR) has been in focus after patient dosing began in the first in human Phase I trial of KT-485 for hidradenitis suppurativa, which triggered a US$20 million milestone payment from Sanofi.

Recent news around KT-485’s first in human trial, fresh KT-579 lupus data, and leadership changes has come alongside mixed short term trading, with a 7 day share price return of 6.86% but a 30 day share price return that is down 6.98%. In contrast, the 1 year total shareholder return of 61.67% and the 3 year total shareholder return of just over 3x point to stronger longer term momentum.

If you are looking beyond Kymera for other opportunities in healthcare and immunology, this is a good moment to scan companies shaping the next wave of therapies using the 39 healthcare AI stocks

With Kymera posting a 1 year total shareholder return of 61.67% and a 3 year return just over 3x, yet still trading below the average analyst price target, investors may be asking whether there is still upside or whether the market has already priced in future growth.

Most Popular Narrative: 33.9% Undervalued

Kymera’s most followed narrative pegs fair value at $118.27 per share compared with a last close of $78.23, which puts that story firmly in focus for anyone weighing the recent run.

The company's strategy to introduce at least one new IND per year could expand their pipeline steadily, offering opportunities for revenue growth from licensing deals or partnerships.
With a significant cash runway extending into mid-2027, Kymera can support its R&D activities without immediate pressure for additional financing, allowing focused investment in high-potential programs that could drive long-term earnings growth.

Want to see what is baked into that fair value gap? The narrative focuses on fast building revenue, improving margins and a future earnings multiple that few early stage biotechs share.

Result: Fair Value of $118.27 (UNDERVALUED)

However, there are still clear pressure points for this story, including high R&D spending alongside ongoing losses and the reliance on partners like Sanofi and Gilead to deliver on key programs.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment split between the recent share price swings and the longer term returns, it makes sense to move quickly and test the numbers yourself, starting with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Kymera has caught your attention, do not stop there. Use this momentum to line up your next set of stock ideas with a clear, focused approach.

• Target stability by filtering for companies with strong fundamentals and low leverage using the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for potential mispricings by scanning companies that pair quality fundamentals with attractive valuations through the 47 high quality undervalued stocks.
• Spot early opportunities by zeroing in on smaller companies with robust financial profiles using the 25 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.